1. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population‐based survey of 15,000 adults. Arch Intern Med. 2001;161:1989‐1996.
2. Ricci JA, Siddique R, Stewart WF, Sandler RS, Sloan S, Farup CE. Upper gastrointestinal symptoms in a US national sample of adults with diabetes. Scand J Gastroenterol. 2000;35:152‐159.
3. Samsom M, Bharucha A, Gerich JE, et al. Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes Metab Res Rev. 2009;25:502‐514.
4. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol Ther. 2008;27:724‐740.
5. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology. 1995;109:755‐765.
6. Intagliata N, Koch KL. Gastroparesis in type 2 diabetes mellitus: prevalence, etiology, diagnosis, and treatment. Curr Gastroenterol Rep. 2007;9:270‐ 279.
7. Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology. 1988;94:739‐744.
8. Lysy J, Israeli E, Strauss‐Liviatan N, Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin‐treated diabetic patients. Neurogastroenterol Motil. 2006; 18:433‐440.
9. Horowitz M, Jones KL, Rayner CK, Read NW. “Gastric” hypoglycaemia – an important concept in diabetes management. Neurogastroenterol Motil. 2006;18:405‐407.
10. Ma J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs. 2009;69:971‐986.
11. Hejazi R, McCallum R. Diabetic gastroparesis: a review of medical treatments. Pract Gastroenterol. 2009;6:10‐20.
12. Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum RW. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg. 2005;9:102‐108.
13. Lin Z, Sarosiek I, Forster J, Damjanov I, Hou Q, McCallum RW. Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis. Neurogastroenterol Motil. 2009;22:56‐61.
14. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement: a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138‐148.
15. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin‐dependent) diabetes mellitus. Diabetologia. 1990;33:675‐680.
16. Sogabe M, Okahisa T, Tsujigami K, et al. Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control. J Gastroenterol. 2005;40: 583‐590.
17. Schvarcz E, Palmér M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabetic Med. 1993;10:660‐663.
18. Schvarcz E, Palmér M, Aman J, Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care. 1995;18: 674‐676.
19. Miller G, Palmer KR, Smith B, Ferrington C, Merrick MV. Smoking delays gastric emptying of solids. Gut. 1989;30:50‐53.
20. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24: 1264‐1269.
21. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol. 2008;36:44‐54.
22. Eliasson B, Björnsson E, Urbanavicius V, et al. Hyperinsulinaemia impairs gastrointestinal motility and slows carbohydrate absorption. Diabetologia. 1995;38:79‐85.
23. Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest. 2000;106:373‐384.
24. Bunck MC, Diamant M, Cornér A, et al. One‐ year treatment with exenatide improves beta‐ cell function, compared with insulin glargine, in metformin‐treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762‐768.
25. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559‐569.
26. Cuthbertson J, Patterson S, O’Harte FP, Bell PM. Addition of metformin to exogenous glucagon‐ like peptide‐1 results in increased serum glucagon‐ like peptide‐1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism. 2010. In Press.
27. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon‐like peptide‐1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91:1916‐1923.
28. Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil. 2002;14:123‐131.
29. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 2000;278: 946‐951.
30. Koch CA, Uwaifo GI. Are gastrointestinal symptoms related to diabetes mellitus and glycemic control? Eur J Gastroenterol Hepatol. 2008;20:822‐825.
31. Heine RJ, Brodows R. Diabetic gastroparesis. N Engl J Med. 2007;357:418‐420.
32. Longstreth GF, Malagelada JR, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med. 1977;86:195‐196.
33. Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double‐blind study. Dig Dis Sci. 1979;24:662‐666.
34. Peringer E, Jenner P, Marsden CD. Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5‐hydroxytryptamine. J Pharm Pharmacol. 1975;27:442‐444.
35. Koch K. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and tretment. Dig Dis Sci. 1999;44:1061‐1075.
36. Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, Van Thiel DH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30:10‐15.
37. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care. 1993;16:1511‐1514.
38. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo‐controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463‐467.
39. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7:25‐32.
40. Snape WJ Jr., Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med. 1982;96:444‐446.
41. Talley N. Diabetic gastropathy and prokinetics. Am J Gastroenterol. 2003;98:264‐271.
42. Tonini M., Cipolina L, Poluuzzi E, et al. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19:379‐390.
43. Parkman HP. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592‐1622.
44. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double‐blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230‐ 1234.
45. Farup CE, Leidy NK, Murray M, Williams GR, Helbers L, Quigley EM. Effect of domperidone on the health‐related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998;21:1699‐1706.
46. Heer M, Müller‐Duysing W, Benes I, et al. Diabetic gastroparesis: treatment with domperidone – a double‐blind, placebo‐controlled trial. Digestion. 1983;27:214‐217.
47. Champion EA. Domperidone (Motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis. Gastroenterol. 1987;82:975.
48. Dumitrascu DL, Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am J Gastroenterol. 2000;95: 316‐317.
49. Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008;6:726‐733.
50. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356:820‐829.
51. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88: 203‐207.
52. Janssens J, Peeters TL, Vantrappen G. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322:1028‐1031.
53. Dive A, Miesse C, Galanti L, et al. Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double‐blind, randomized, placebo‐controlled study. Crit Care Med. 1995;23:1356‐1362.
54. Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT‐229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut. 2001;49:395‐401.
55. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT‐229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double‐blind placebo‐ controlled trial. Aliment Pharmacol Ther. 2000;14:1653‐1661.
56. McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis – a randomized, multicentre, placebo‐controlled study. Aliment Pharmacol Ther. 2007;26: 1121‐1130.
57. Hawkyard CV, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother. 2007;59:347‐358.
58. McCallum RW, Prakash C, Campoli‐Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal disorders. Drugs. 1988;36:652‐681.
59. Champion MC. Management of idiopathic, diabetic and miscellaneous gastroparesis with cisapride. Scand J Gastroenterol Suppl. 1989;165:44‐52. Discussion:52‐53.
60. Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJ. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology. 1987;93: 311‐315.
61. Horowitz M, Maddox A, Harding PE, et al. Effect of cisapride on gastric and esophageal emptying in insulin‐dependent diabetes mellitus. Gastroenterology. 1987;92:1899‐1907.
62. McHugh S, Lico S, Diamant NE. Cisapride vs. metoclopramide. Dig Dis Sci. 1992;37:997‐1001.
63. Havelund T, Oster‐Jørgensen E, Eshøj O, Larsen ML, Lauritsen K. Effects of cisapride on gastroparesis in patients with insulin‐dependent diabetes mellitus. Acta Medica Scandinavica. 1987;222:339‐343.
64. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85: 4908‐4911.
65. Peino R, Baldelli R, Rodriguez‐Garcia J, et al. Ghrelin‐induced growth hormone secretion in humans. Eur J Endocrinol. 2000;143:R11‐R14.
66. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone‐releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141:4255‐4261.
67. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth‐hormone‐
releasing acylated peptide from stomach. Nature. 1999;402:656‐660.
68. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974‐ 977.
69. Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut. 2006;55:327‐333.
70. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.
71. Druce MR. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond). 2005;29:1130‐1136.
72. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer‐related anorexia/cachexia: a randomised, placebo‐controlled, double‐blind, double‐crossover study. Br J Cancer. 2008;98: 300‐308.
73. Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut. 2005;54:1693‐1698.
74. Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore AJ. The Ghrelin agonist TZP‐ 101 for management of postoperative ileus after partial colectomy: a randomized, dose‐ranging, placebo‐controlled clinical trial. Dis Colon Rectum. 2010;53:126‐134.
75. Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP‐101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo‐controlled study. Neurogastroenterol Motil. 2010. In press.
76. Ejskjaer N, Vestergaard ET, Hellström PM, et al. Ghrelin receptor agonist (TZP‐101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther. 2009;29:1179‐1187.
77. Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP‐101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first‐in‐human study. J Clin Pharmacol. 2008;48:193‐202.
78. Wang CP, Kao CH, Chen WK, Lo WY, Hsieh CL. A single‐blinded, randomized pilot study evaluating
effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis. J Altern Complement Med. 2008;14:833‐839.
79. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986;90:1919‐1925.
80. Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986;91:94‐99.
81. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186‐1194.
82. Pehlivanov N, Pasricha PJ. Achalasia: botox, dilatation or laparoscopic surgery in 2006. Neurogastroenterol Motil. 2006;18:799‐804.
83. Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol 2006;101:1129‐1139.
84. Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized‐controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251‐1258.
85. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416‐423.
86. NICE. Interventional procedure overview: gastroelectrical stimulation for gastroparesis. Clinical guidelines. October 12, 2004. Available at 
87. Anand C, Al‐Juburi A, Familoni B, et al. Gastric electrical stimulation is safe and effective: a long‐term study in patients with drug‐refractory gastroparesis in three regional centers. Digestion. 2007;75:83‐89.
88. Abell TL, Malinowski S, Minocha A. Nutrition aspects of gastroparesis and therapies for drug‐ refractory patients. Nutr Clin Pract. 2006;21:23‐33.
89. Cutts TF, Luo J, Starkebaum W, Rashed H, Abell TL. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long‐term health care benefits? Neurogastroenterol Motil. 2005;17:35‐43.
90. Maranki J, Parkman HP. Gastric electric stimulation for the treatment of gastroparesis. Curr Gastroenterol Rep. 2007;9:286‐294.